Meeting Details

The 9th Annual General Meeting of Astonea Labs Limited is scheduled to be held on Friday, 21st August, 2026 at 11:30 A.M. at Mercure Hotel, Plot No. 51, Near Tribune Chowk, Industrial Area Phase II, Chandigarh - 160002. The meeting will be conducted in physical mode.

Key Dates and Logistics

  • Cut-off date for determining eligibility: Friday, 14th August, 2026
  • Remote e-voting period: Tuesday, 18th August, 2026 at 09:00 A.M. to Thursday, 20th August, 2026 at 05:00 P.M.
  • E-voting agency: National Securities Depository Limited (NSDL)
  • Scrutinizer for e-voting process: Mr. Sahil Malhotra (Membership No. A38204 / COP No. 14791)
  • Book closure period: Saturday, August 15, 2026 to Friday, August 21, 2026 (both days inclusive)

Business to be Transacted

Ordinary Business

1. Adoption of Audited Standalone Financial Statements: To receive, consider and adopt the audited standalone financial statements for the financial year ended 31st March, 2026, together with reports of the Board of Directors and Auditors thereon.

2. Adoption of Audited Consolidated Financial Statements: To receive, consider and adopt the audited consolidated financial statements for the financial year ended 31st March, 2026, together with the report of the Auditors thereon.

3. Re-appointment of Director: To re-appoint Ms. Pooja Singh (DIN: 10547745) who retires by rotation and being eligible offers herself for re-appointment. Ms. Singh is 32 years old, holds a Bachelor of Pharmacy degree, and has over eight years of experience in pharmaceutical quality assurance and regulatory affairs. Her current remuneration is approximately ₹6.21 lakhs (FY 2025-26).

Special Business

4. Ratification of Cost Auditor Remuneration: To ratify the remuneration of ₹75,000/- (Rupees Seventy-Five Thousand only) plus applicable taxes and reimbursement of actual out-of-pocket expenses payable to M/s. Balwinder & Associates, Cost Accountants (Firm Registration No. 000201) for conducting cost audit for FY ending 31st March 2027.

5. Alteration of Memorandum of Association: To approve alteration in the Object Clause (Clause III(A)) of the MOA to expand the company's business activities to include:

  • Manufacturing, formulation, processing, development, refinement, import, export, buying, selling, distribution, marketing, wholesale and/or retail trade of pharmaceuticals, antibiotics, drugs, medicines, biologicals, nutraceuticals, healthcare products, ayurvedic products, dietary supplements, medicinal preparations, vaccines, chemicals, and related products
  • Carrying on business of marketing, promotion, distribution and sale of products through recognized commercial channels including retail trade, wholesale trade, institutional sales, franchise arrangements, e-commerce platforms, and digital marketplaces

6. Incorporation and Investment in Subsidiary Companies: To approve the incorporation and investment in one or more subsidiary company(ies) in India. The members had previously approved an aggregate limit of ₹100 crore under Section 186 of the Companies Act, 2013 at an EGM held on 27th March, 2026.

Shareholder Information

  • Members can vote remotely through NSDL e-voting system or in person at the meeting
  • Proxy forms must be deposited at the registered office not less than 48 hours before the meeting
  • Corporate members must send certified copies of Board Resolution authorizing representatives
  • Members holding physical shares must ensure KYC compliance with the RTA, KFin Technologies Ltd

Financial Impact

  • Cost auditor remuneration: ₹75,000 + applicable taxes + out-of-pocket expenses
  • Subsidiary incorporation/investment: Within previously approved ₹100 crore limit under Section 186
  • No specific financial impact quantified for MOA alteration

Additional Information

  • Company CIN: L24304CH2017PLC041482
  • GSTIN: 06AAPCA4446E1ZP
  • Corporate Office: Plot No. 63, Industrial Area, Phase-2, Industrial Estate, Panchkula, Haryana, India-134113
  • Company Secretary & Compliance Officer: Mr. Ankit Kapoor (M.NO. A75702)